Top Markets
#1 GEKKO GEKKO +52.86%
#2 TENDIES TENDIES +49.51%
#3 Helium Helium +48.71%
#4 Pons Pons +43.17%
#5 ADO Protocol ADO Protocol +39.18%
#6 Prom Prom +31.04%
#7 Collector Crypt Collector Crypt +24.28%
#8 Nillion Nillion +19.84%
#9 龙虾 (Lobster) 龙虾 (Lobster) +19.38%
#10 o1.exchange o1.exchange +18.11%
Coin of the day
GEKKO GEKKO
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Provention Bio, Inc. Provention Bio, Inc.

Provention Bio, Inc.

PRVB
Classifica tra le azioni #9449
Provention Bio, Inc. is a clinical-stage biopharmaceutical firm dedicated to... Provention Bio, Inc. is a clinical-stage biopharmaceutical firm dedicated to discovering and bringing to market therapies aimed at intercepting and preventing autoimmune disorders. Their lead investigational candidate, PRV-031 (teplizumab, a monoclonal antibody), is currently in a Phase III clinical trial for the interception of Type 1 Diabetes (T1D). Another asset, PRV-3279, has successfully completed its Phase Ib clinical trial for the treatment of lupus. The company is also developing PRV-101, a vaccine targeting coxsackie virus B (CVB) to prevent both acute CVB infections and the onset of T1D. Additionally, PRV-015 is undergoing a Phase IIb clinical trial, offering a potential treatment for celiac disease that does not respond to a gluten-free diet. Provention Bio has established strategic partnerships to advance its pipeline. This includes a licensing and collaboration agreement with Amgen Inc. for PRV-015, described as a novel anti-IL-15 monoclonal antibody, for the continued development against gluten-free diet non-responsive celiac disease. Furthermore, a strategic alliance with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. focuses on the development and commercialization of PRV-3279 in Greater China. PRV-3279 is characterized as a bispecific antibody-based molecule designed to target B cell surface proteins CD32B and CD79B. Founded in 2016, Provention Bio, Inc. maintains its headquarters in Red Bank, New Jersey.
Prezzo delle azioni
$24.98
Ultima sincronizzazione: 2023-04-27
Capitalizzazione di mercato
$1.01B
Variazione (1 giorno)
0.00%
Variazione (1 anno)
0.00%
Paese
US
Scambia Provention Bio, Inc. (PRVB)

Categoria

Healthcare
Ricavi di Provention Bio, Inc. (PRVB)
Ricavi nel Aug 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di Provention Bio, Inc., i ricavi attuali dell'azienda (TTM) sono pari a 0. Nel 2026, l'azienda ha registrato ricavi di 0 uguale a i ricavi dell'anno 2026, che erano pari a 0. I ricavi rappresentano l'importo totale generato dalla vendita di beni o servizi. A differenza degli utili, le spese non vengono detratte.
Storico dei ricavi per Provention Bio, Inc. da 2026 a 2026
Ricavi alla fine di ogni anno
Anno Ricavi Cambia
Non abbastanza dati per le date fornite.
Ricavi di aziende simili o concorrenti
Azienda Ricavi Differenza nei ricavi Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH